NCT03065400View on ClinicalTrials.gov

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

May 28, 2020

Study Completion Date

May 28, 2020

Conditions
Chronic Phase MyelofibrosisPrimary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPolycythemia Vera
Interventions
DRUG

Pembrolizumab

200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

10467

Montefiore Medical Center Division of Hematology, Department of Oncology, The Bronx

02114

Harvard Medical School Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Montefiore Medical Center

OTHER

lead

John Mascarenhas

OTHER

NCT03065400 - PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | Biotech Hunter | Biotech Hunter